Trial Information

Summary: Phase II - ACC-001 Vaccine treatment for mild to moderate Alzheimer's Disease, trial study

This study opens in November.

The Alzheimer's vaccine is not a typical vaccine. It does not prevent Alzheimer's disease. However, it is a new approach to treatment. It is called a vaccine because the drug will actually harness the patient's immune system to treat the disease.

Alzheimer's disease is believed by many to be caused by accumulation of protein in the brain. Other Alzheimer's disease treatments have aimed at slowing the buildup of protein in the brain. The vaccine works differently. The vaccine activates the patient immune system to actually remove the protein.

Patient Inclusion Criteria: Need clinical diagnosis of mild to moderate AD Must be within age 50-85 years old Caretaker or study partner required Patient must have had a stable dose of current AD treatments for four months prior to starting study

Patient Exclusion Criteria: Certain medical conditions Patient being treated with certain medications

For more information,

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:32:47 AM